{
  "processed_count": 10,
  "processed_date": "2025-04-09T15:30:00.000Z",
  "studies": [
    {
      "nctrialId": "HC-2022-001",
      "title": "Efficacy and Safety of Novel Antibody Treatment for Early-Stage Rheumatoid Arthritis",
      "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Study of IL-17 Inhibition in Early-Stage Rheumatoid Arthritis",
      "sponsor": "University of Toronto Medical Research",
      "indication": "Rheumatoid Arthritis",
      "phase": "Phase 2",
      "fileName": "HC-2022-001.json",
      "fileSize": 0,
      "date": "2022-03-15",
      "completionDate": "2024-06-30",
      "drugName": "Rheumazol-17 (IL-17 antagonist)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Recruiting",
      "description": "This study aims to evaluate the efficacy and safety of an IL-17 antagonist monoclonal antibody in patients with early-stage rheumatoid arthritis who have not received prior biologic therapy.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-75 years\n- Diagnosis of rheumatoid arthritis according to ACR/EULAR 2010 criteria\n- Disease duration <2 years\n- Active disease defined as DAS28-CRP ≥3.2\n- Inadequate response to at least one conventional DMARD\n\nExclusion Criteria:\n- Previous exposure to any biologic DMARD\n- History of tuberculosis or positive IGRA test\n- Live vaccines within 4 weeks prior to randomization\n- Pregnancy or breastfeeding\n- Significant comorbid conditions"
    },
    {
      "nctrialId": "HC-2022-015",
      "title": "Novel microbiome therapy for irritable bowel syndrome",
      "officialTitle": "A Randomized Controlled Trial of Fecal Microbiota Transplantation for the Treatment of Irritable Bowel Syndrome With Diarrhea",
      "sponsor": "McGill University Health Centre",
      "indication": "Irritable Bowel Syndrome",
      "phase": "Phase 3",
      "fileName": "HC-2022-015.json",
      "fileSize": 0,
      "date": "2022-05-21",
      "completionDate": "2024-05-21",
      "drugName": "FMT-IBS (fecal microbiota transplant)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Active, not recruiting",
      "description": "This clinical trial evaluates the efficacy of fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome compared to placebo. The primary outcome is the proportion of patients who achieve clinical response at 12 weeks.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-65 years\n- Rome IV criteria for IBS-D\n- Symptoms for at least 6 months\n- Failure of at least two conventional therapies\n- Willing to discontinue probiotics 4 weeks before screening\n\nExclusion Criteria:\n- History of inflammatory bowel disease\n- Celiac disease\n- Major gastrointestinal surgery\n- Antibiotic use within 3 months of screening\n- Severe psychiatric disorders\n- Pregnancy or breastfeeding"
    },
    {
      "nctrialId": "HC-2022-079",
      "title": "Multi-center assessment of novel gene therapy for hemophilia A",
      "officialTitle": "A Phase 1/2, Open-Label, Dose-Escalation Study Evaluating the Safety and Efficacy of a Novel AAV-Based Gene Therapy in Adult Patients with Severe Hemophilia A",
      "sponsor": "Canadian Blood Services Research Foundation",
      "indication": "Hemophilia A",
      "phase": "Phase 1/Phase 2",
      "fileName": "HC-2022-079.json",
      "fileSize": 0,
      "date": "2022-09-04",
      "completionDate": "2025-09-04",
      "drugName": "HAV-GTx (adeno-associated viral vector)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Active, recruiting",
      "description": "This is a first-in-human, multi-center, open-label study designed to evaluate the safety and efficacy of an adeno-associated virus (AAV) vector expressing human Factor VIII in patients with severe hemophilia A. Participants will receive a single intravenous infusion of the investigational gene therapy at escalating doses.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Males aged 18-65 years\n- Severe hemophilia A (FVIII activity <1%)\n- History of ≥150 exposure days to FVIII products\n- No history of FVIII inhibitors\n- No evidence of liver disease\n- Negative for anti-AAV antibodies\n\nExclusion Criteria:\n- History of thromboembolic events\n- HIV positive with CD4 count <200 cells/μL\n- Active hepatitis B or C infection\n- Prior gene therapy or liver transplantation\n- Participation in another interventional study within 3 months"
    },
    {
      "nctrialId": "HC-2022-106",
      "title": "Novel treatment for treatment-resistant depression in older adults",
      "officialTitle": "A Randomized, Double-Blind, Active-Controlled Study of a Novel NMDA Receptor Modulator in Elderly Patients with Treatment-Resistant Depression",
      "sponsor": "Centre for Addiction and Mental Health",
      "indication": "Treatment-Resistant Depression",
      "phase": "Phase 2",
      "fileName": "HC-2022-106.json",
      "fileSize": 0,
      "date": "2022-11-15",
      "completionDate": "2024-05-15",
      "drugName": "NDR-457 (NMDA receptor modulator)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Active, not recruiting",
      "description": "This study evaluates the efficacy and safety of a novel NMDA receptor modulator in elderly patients with treatment-resistant depression, compared to standard of care. The primary outcome is change in Montgomery-Åsberg Depression Rating Scale (MADRS) score at 4 weeks.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 65-85 years\n- Major Depressive Disorder (DSM-5 criteria)\n- Inadequate response to ≥2 antidepressants from different classes\n- MADRS score ≥26 at screening and baseline\n- Mini-Mental State Examination score ≥24\n\nExclusion Criteria:\n- History of bipolar disorder or psychotic disorders\n- Current substance use disorder\n- Clinically significant neurological disorders\n- History of seizure disorder\n- Suicidal ideation with intent within 6 months\n- Unstable medical conditions"
    },
    {
      "nctrialId": "HC-2023-012",
      "title": "Efficacy of precision oncology approach for advanced breast cancer",
      "officialTitle": "A Randomized Phase 3 Trial Comparing Standard of Care versus Genomically-Directed Therapy Selection in Patients with HR+/HER2- Metastatic Breast Cancer",
      "sponsor": "BC Cancer Agency",
      "indication": "Advanced Breast Cancer",
      "phase": "Phase 3",
      "fileName": "HC-2023-012.json",
      "fileSize": 0,
      "date": "2023-01-18",
      "completionDate": "2026-01-18",
      "drugName": "Multiple targeted therapies based on genomic profiling",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Recruiting",
      "description": "This trial compares standard therapy selection versus genomically-directed therapy selection in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Patients in the experimental arm will receive treatment based on comprehensive genomic profiling results.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged ≥18 years\n- Histologically confirmed HR+/HER2- advanced breast cancer\n- Measurable disease per RECIST v1.1\n- ECOG performance status 0-1\n- Adequate organ function\n- Progression on or after at least one line of endocrine therapy\n\nExclusion Criteria:\n- Brain metastases unless treated and stable\n- Prior chemotherapy for metastatic disease\n- Active second malignancy\n- Significant cardiovascular disease\n- Uncontrolled intercurrent illness"
    },
    {
      "nctrialId": "HC-2023-045",
      "title": "Novel immunotherapy combination for advanced melanoma",
      "officialTitle": "A Randomized, Open-Label Phase 2 Study of Anti-LAG-3 Antibody in Combination with Pembrolizumab in Patients with Advanced Melanoma who Progressed on Anti-PD-1 Therapy",
      "sponsor": "Princess Margaret Cancer Centre",
      "indication": "Advanced Melanoma",
      "phase": "Phase 2",
      "fileName": "HC-2023-045.json",
      "fileSize": 0,
      "date": "2023-03-22",
      "completionDate": "2025-12-31",
      "drugName": "Anti-LAG-3 antibody + pembrolizumab",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Recruiting",
      "description": "This study evaluates the efficacy and safety of an anti-LAG-3 antibody in combination with pembrolizumab in patients with advanced melanoma who progressed on prior anti-PD-1 therapy. The primary endpoint is objective response rate per RECIST v1.1.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged ≥18 years\n- Histologically confirmed unresectable stage III or IV melanoma\n- Documented progression on anti-PD-1 therapy\n- At least one measurable lesion per RECIST v1.1\n- ECOG performance status 0-1\n- Adequate organ function\n\nExclusion Criteria:\n- Active autoimmune disease requiring systemic treatment\n- Prior anti-LAG-3 therapy\n- Untreated CNS metastases\n- History of pneumonitis\n- Active infection requiring therapy\n- Pregnancy or breastfeeding"
    },
    {
      "nctrialId": "HC-2023-078",
      "title": "Novel therapy for Duchenne muscular dystrophy",
      "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of a Novel Utrophin Modulator in Ambulatory Boys with Duchenne Muscular Dystrophy",
      "sponsor": "Montreal Neurological Institute",
      "indication": "Duchenne Muscular Dystrophy",
      "phase": "Phase 2",
      "fileName": "HC-2023-078.json",
      "fileSize": 0,
      "date": "2023-06-11",
      "completionDate": "2025-06-11",
      "drugName": "UTX-101 (utrophin modulator)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Recruiting",
      "description": "This study evaluates the safety and efficacy of a novel utrophin modulator in ambulatory boys with Duchenne muscular dystrophy. The primary outcome is change in the North Star Ambulatory Assessment (NSAA) total score at 48 weeks.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Boys aged 5-12 years\n- Genetically confirmed diagnosis of DMD\n- Able to walk ≥75 meters unassisted in 6-minute walk test\n- Stable regimen of corticosteroids for ≥6 months\n- North Star Ambulatory Assessment score ≥8\n\nExclusion Criteria:\n- Use of investigational drugs within 3 months\n- Prior gene therapy or cell-based therapy\n- Planned or anticipated surgery during study\n- Clinically significant cardiac or pulmonary dysfunction\n- Inability to comply with study procedures"
    },
    {
      "nctrialId": "HC-2023-109",
      "title": "Novel CRISPR-based therapy for cystic fibrosis",
      "officialTitle": "A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety and Efficacy of CRISPR/Cas9-Mediated Gene Editing Delivered via Lipid Nanoparticles in Adult Patients with Cystic Fibrosis",
      "sponsor": "Hospital for Sick Children Toronto",
      "indication": "Cystic Fibrosis",
      "phase": "Phase 1",
      "fileName": "HC-2023-109.json",
      "fileSize": 0,
      "date": "2023-08-05",
      "completionDate": "2025-08-05",
      "drugName": "CF-CRISPR-LNP (CRISPR/Cas9 editing therapy)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Active, recruiting",
      "description": "This is a first-in-human study evaluating the safety and preliminary efficacy of a CRISPR/Cas9 gene editing therapy delivered via lipid nanoparticles to correct the most common CFTR mutation (F508del) in patients with cystic fibrosis. The therapy is administered via nebulization.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-40 years\n- Confirmed diagnosis of CF with homozygous F508del mutation\n- FEV1 ≥40% and ≤90% predicted\n- Clinically stable without pulmonary exacerbation for 4 weeks\n- Willing to discontinue CFTR modulators 4 weeks prior to dosing\n\nExclusion Criteria:\n- Active pulmonary infection with B. cepacia or M. abscessus\n- Significant hemoptysis (>60 mL) within 6 months\n- History of solid organ transplantation\n- Abnormal liver function (ALT or AST >3x ULN)\n- Pregnancy or breastfeeding\n- Current smoker or vaping"
    },
    {
      "nctrialId": "HC-2023-154",
      "title": "Novel therapy for treatment-resistant hypertension",
      "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Novel Dual Endothelin Receptor Antagonist in Patients with Treatment-Resistant Hypertension",
      "sponsor": "Montreal Heart Institute",
      "indication": "Treatment-Resistant Hypertension",
      "phase": "Phase 2",
      "fileName": "HC-2023-154.json",
      "fileSize": 0,
      "date": "2023-10-18",
      "completionDate": "2025-10-18",
      "drugName": "MHI-731 (dual endothelin receptor antagonist)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Not yet recruiting",
      "description": "This study evaluates the efficacy and safety of a novel dual endothelin receptor antagonist in patients with treatment-resistant hypertension. The primary endpoint is change from baseline in mean 24-hour ambulatory systolic blood pressure at 12 weeks.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-75 years\n- Diagnosis of true treatment-resistant hypertension\n- Office systolic BP ≥140 mmHg despite use of ≥3 antihypertensive medications\n- Mean 24-hour ambulatory systolic BP ≥130 mmHg during screening\n- Stable medication regimen for ≥4 weeks\n\nExclusion Criteria:\n- Secondary hypertension\n- Severe renal impairment (eGFR <30 mL/min/1.73m²)\n- Significant valvular heart disease\n- History of heart failure with reduced ejection fraction\n- Clinically significant abnormalities on screening ECG\n- Pregnancy or breastfeeding"
    },
    {
      "nctrialId": "HC-2023-189",
      "title": "Novel treatment for severe eosinophilic asthma",
      "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Novel Anti-TSLP Monoclonal Antibody in Adults with Severe Eosinophilic Asthma",
      "sponsor": "University of British Columbia",
      "indication": "Severe Eosinophilic Asthma",
      "phase": "Phase 3",
      "fileName": "HC-2023-189.json",
      "fileSize": 0,
      "date": "2023-12-10",
      "completionDate": "2026-12-10",
      "drugName": "BC-401 (anti-TSLP monoclonal antibody)",
      "source": "Health Canada Clinical Trials Database",
      "studyType": "Interventional",
      "status": "Recruiting",
      "description": "This study evaluates the efficacy and safety of a novel anti-TSLP monoclonal antibody in adults with severe eosinophilic asthma. The primary endpoint is the annualized rate of asthma exacerbations over 52 weeks of treatment.",
      "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-75 years\n- Physician-diagnosed asthma for ≥2 years\n- Blood eosinophil count ≥300 cells/μL within past 12 months\n- ACQ-6 score ≥1.5 at screening\n- Pre-bronchodilator FEV1 <80% predicted\n- ≥2 documented asthma exacerbations requiring systemic corticosteroids in the past 12 months\n- Maintenance treatment with high-dose ICS plus LABA\n\nExclusion Criteria:\n- Diagnosis of COPD or other significant lung disease\n- Current smoker or former smoker with ≥10 pack-years\n- Parasitic infection within past 6 months\n- Clinically significant comorbidity\n- Prior biologic therapy for asthma within washout period\n- Pregnancy or breastfeeding"
    }
  ]
}